481630-46-0

Upstream product

• 3377-71-7 N-benzylindole 
• 100-39-0 benzyl bromide 
• 710975-90-9 1-(1-benzyl-1H-indol-3-yl)-2,2-dimethylpropan-1-one 
• 10075-50-0 5-bromo-1H-indole 
• 10075-51-1 1-benzyl-5-bromo-1H-indole 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 

Downstream Products

• 735271-92-8 [1-benzyl-5-(4-trifluoromethoxy-phenyl)-1H-indol-3-yl]-oxo-acetyl chloride 
• 735271-93-9 methyl 2-{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}-2-oxoacetate 
• 393105-53-8 2-(1-benzyl-5-(4-(trifluoromethoxy)phenyl)-1H-indol-3-yl)oxoacetic acid 
• 481630-47-1 ethyl 2{-1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}-2-oxoacetate 

Relevant academic research and scientific papers

Regiocontrolled Direct C?H Arylation of Indoles at the C4 and C5 Positions

An effective and practical strategy has been established for the direct and site-selective arylation of indoles at the C4 and C5 positions with the aid of a readily accessible, cheap, and removable pivaloyl directing group at the C3 position. This transfo

Inhibitors Of PAI-1 For Treatment Of Muscular Conditions

This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization

Indole oxoacetic acid derivatives were prepared and evaluated for in vitro binding to and inactivation of human plasminogen activator inhibitor-1 (PAI-1). SAR based on biochemical, physiological, and pharmacokinetic attributes led to identification of tip

Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

This invention provides indole oxo-acetyl amino acetic acid derivatives which are useful as inhibitors of plasminogen activator inhibitor-1 (PAl-1) useful for treating fibrinolytic disorders, the compounds having the structure: wherein: R1 is a

Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.